LOGO

Checklist: Hope And Help For A Painful Skin Condition

Sanofi offers a novel treatment option for those who struggle with stubborn eczema.
Posted on Dec 5, 2021 | 04:05pm
Brought to you by Watch

An estimated 31.6 percent of people in the U.S. are afflicted with eczema, or atopic dermatitis, a painful and often embarrassing condition in which patches of their skin become inflamed, itchy, red, cracked, and sometimes blistered. While some respond well to topical prescription lotions and creams, including corticosteroids, others can't tolerate them or find they simply don't provide a significant level of eczema relief. That's where Sanofi's DUPIXENT® , an injection that's self-administered every other week, may offer new hope.

DUPIXENT®  targets immune mediators within a physiological pathway associated with atopic dermatitis; can be used with or without topical corticosteroids; and is recommended only for people 12 or older with moderate-to-severe eczema. If you think you may be ready to "help heal your skin from within" as Sanofi likes to say in their DUPIXENT® commercials, talk to your doctor or eczema specialist today. 

For product information, proscribing information, medication guide, and possible side effects, visit dupixent.com.

Photo Credit: m-imagephotography/Getty Images.